Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144722 | 0.82 | KDM4C (0.56) | KDM5CKDM4CSCDSCD5VNN1 | |
| SCHEMBL17145009 | 0.81 | CXCR4 (0.35) | CXCR4KDM5CKDM4CPDE7BSCD | |
| SCHEMBL19741663 | 0.80 | KDM4C (0.56) | KDM5CKDM4CSCDSCD5VNN1 | |
| SCHEMBL21482061 | 0.79 | CXCR4 (0.56) | CXCR4RECQLKDM5CKDM4CLMNA | |
| SCHEMBL17145118 | 0.77 | JMJD6 (0.46) | KDM5CKDM4C | |
| SCHEMBL17144910 | 0.76 | JMJD6 (0.42) | KDM5CKDM4CVNN1 | |
| SCHEMBL17144777 | 0.74 | KDM4C (0.58) | KDM5CKDM4CPDE7BSCDSCD5 | |
| SCHEMBL17144874 | 0.70 | PDE7B (0.33) | CXCR4PDE7B | |
| SCHEMBL14837570 | 0.67 | SIGMAR1 (0.52) | LMNA | |
| SCHEMBL13573578 | 0.65 | LMNA (0.47) | PDE7BIDH1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS APS (DK) | 2017-12-28 | — | — | US | disclosed |
| EP-3126345-A1 | INHIBITORS OF HISTONE DEMETHYLASES | Gilead Sciences, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015153498-A1 | INHIBITORS OF HISTONE DEMETHYLASES | EPITHERAPEUTICS, APS (DK) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170369444-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM3A, KDM1A | CXCR4 4368/4885RECQL 214/4885KDM5C 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.